The invention relates to methods for preparing an olive (Olea europaea subsp. europaea), preferably acebuche (Olea europaea subsp. europaea var. sylvestris) composition, the olive or acebuche composition as prepared, and uses thereof in the prevention or treatment of a bacterial or fungal infection in mammals, preferably infection by antibiotic resistant or multi-resistant bacteria. Other uses relate to functional food additives, in particular an animal feed additive, or to uses in cosmetics.

The invention relates to methods for preparing an olive (Olea europaea subsp. europaea), preferably acebuche (Olea europaea subsp. europaea var. sylvestris) composition, the olive or acebuche composition as prepared, and uses thereof in the prevention or treatment of a bacterial or fungal infection in mammals, preferably infection by antibiotic resistant or multi-resistant bacteria. Other uses relate to functional food additives, in particular an animal feed additive, or to uses in cosmetics.

Methods of treating alcoholic hepatitis (AH) are provided. For instance, the methods may comprise administering 5-cholesten-3,25-diol, 3-sulfate (25HC3S) or a salt thereof.

A method of increasing the solubility of a water-insoluble or slightly water-soluble hydrophobic organic compound in an aqueous solvent includes adding a saponin component selected from escin, glycyrrhizin, and Quillaya saponaria extract to the aqueous solvent in an amount sufficient to trigger the formation of micelles, wherein in a first step the hydrophobic organic compound is pre-dissolved in an organic solvent, and in a second step the organic solvent comprising the pre-dissolved compound is admixed to the aqueous solvent, whereby at least a part of the insoluble or slightly soluble hydrophobic organic compound gets solubilized and dissolved in the aqueous solvent, yielding an aqueous composition having an increased concentration of said organic compound dissolved therein. Also indicated are pharmaceutical or cosmetic compositions including a water-insoluble or slightly water-soluble organic compound dissolved in an aqueous solvent at substantially increased concentrations.

A method of increasing the solubility of a water-insoluble or slightly water-soluble hydrophobic organic compound in an aqueous solvent includes adding a saponin component selected from escin, glycyrrhizin, and Quillaya saponaria extract to the aqueous solvent in an amount sufficient to trigger the formation of micelles, wherein in a first step the hydrophobic organic compound is pre-dissolved in an organic solvent, and in a second step the organic solvent comprising the pre-dissolved compound is admixed to the aqueous solvent, whereby at least a part of the insoluble or slightly soluble hydrophobic organic compound gets solubilized and dissolved in the aqueous solvent, yielding an aqueous composition having an increased concentration of said organic compound dissolved therein. Also indicated are pharmaceutical or cosmetic compositions including a water-insoluble or slightly water-soluble organic compound dissolved in an aqueous solvent at substantially increased concentrations.

A pressurized medicinal composition comprising at least 40%, by weight, of liquid carbon dioxide, a fluid that forms a homogeneous solution with liquid carbon dioxide, and at least one active pharmaceutical ingredient dissolved or suspended in the composition. The composition may have a liquid to supercritical transition temperature greater than 40° C. Also, metered dose inhalers comprising an actuator, and a canister equipped with a metering valve, wherein the canister houses a reservoir comprising a pressurized carrier fluid mixture for dissolving or suspending at least one active pharmaceutical ingredient, the carrier fluid mixture comprising liquid carbon dioxide and a second component that is a liquid at room temperature and pressure.

A pressurized medicinal composition comprising at least 40%, by weight, of liquid carbon dioxide, a fluid that forms a homogeneous solution with liquid carbon dioxide, and at least one active pharmaceutical ingredient dissolved or suspended in the composition. The composition may have a liquid to supercritical transition temperature greater than 40° C. Also, metered dose inhalers comprising an actuator, and a canister equipped with a metering valve, wherein the canister houses a reservoir comprising a pressurized carrier fluid mixture for dissolving or suspending at least one active pharmaceutical ingredient, the carrier fluid mixture comprising liquid carbon dioxide and a second component that is a liquid at room temperature and pressure.

A prophylactic or therapeutic pharmaceutical agent for HIV infectious diseases, said pharmaceutical agent being characterized by comprising a combination of: (A) a compound represented by formula (I) (wherein ring A represents a non-aromatic heterocyclic ring; ring B represents a benzene ring or a pyridine ring; Q represents —NHC(O)— or the like: each R.sup.1 independently represents a halogen atom or the like: each of R.sup.2a and R.sup.2b independently represents a hydrogen atom or the like: R.sup.3 represents an alkyl group or a haloalky 1 group: R.sup.4 represents a hydrogen atom or an alkyl group: and n represents an integer from 1 to 3) or a pharmaceutically acceptable salt thereof, and (B) a compound having an anti-HIV effect or a pharmaceutically acceptable salt thereof.

##STR00001##

A prophylactic or therapeutic pharmaceutical agent for HIV infectious diseases, said pharmaceutical agent being characterized by comprising a combination of: (A) a compound represented by formula (I) (wherein ring A represents a non-aromatic heterocyclic ring; ring B represents a benzene ring or a pyridine ring; Q represents —NHC(O)— or the like: each R.sup.1 independently represents a halogen atom or the like: each of R.sup.2a and R.sup.2b independently represents a hydrogen atom or the like: R.sup.3 represents an alkyl group or a haloalky 1 group: R.sup.4 represents a hydrogen atom or an alkyl group: and n represents an integer from 1 to 3) or a pharmaceutically acceptable salt thereof, and (B) a compound having an anti-HIV effect or a pharmaceutically acceptable salt thereof.

##STR00001##

The present invention describes liposome formulations comprising a phospholipid, cholesterol and a fatty acid compound or fatty acid containing compound. Also, various medical uses of the liposome formulation are described.